Colin Brenan
CEO and Founder | 1CellBiO Inc.
Boston, MA, UNITED STATES
Colin Brenan is a serial entrepreneur with expertise in research, project management, and financing of early-stage life science companies.
Biography
Colin Brenan is a serial entrepreneur and senior executive with 30 years experience in scientific research, project management, product development, strategic marketing and financing of early-stage life science companies.
He is the author of 50+ peer-reviewed publications, book chapters and reports advancing the science and technology of confocal microscopy, hyper spectral imaging, microsurgical robotics and bio-microsystems and inventor on 24 US & foreign patents and 20+ pending patent applications. Colin specializes in inventing, developing, and commercializing life science technologies, and has significant experience with helping start-up companies to form and seek financing.
Colin was the Founder and former chair of the Boston Chapter of the IEEE Engineering in Medicine and Biology Society (IEEE-EMBS) and a Senior Member of the IEEE. He holds Bachelor's, Master's and Doctorate degrees from McGill University in Physics, Electrical Engineering, and Biomedical engineering, respectively.
Industry Expertise (2)
Biotechnology
Research
Areas of Expertise (8)
Business Development
Commercialization of Life Science Technologies
Product Development
Lifesciences
Start-Ups
Research & Development
Entrepreneurship
Intellectual Property Strategy
Education (3)
McGill Unviersity: Ph.D., Biomedical Engineering 1997
McGill University: M.Eng., Electrical Engineering 1989
McGill University: B.Sc., Physics 1982
Multimedia
Publications:
Documents:
Videos:
Audio/Podcasts:
Affiliations (1)
- National Institute of Health
Links (1)
Selected Media Appearances (1)
1CellBio Announces Custom Targeted Bead Program to Accelerate Next Phase in Single-Cell Analysis
Business Wire online
2019-04-17
“This new program enables researchers to focus their sequencing depth on their genes of interest rather than the full transcriptome,” said Colin J.H. Brenan, PhD, Chief Executive Officer at 1CellBio. “We believe the ability to customize and target transcriptional regions of interest will accelerate clinical and pharmaceutical research applications of single-cell RNA-seq...”
Patents (2)
Assay apparatus and method using microfluidic arrays
US7682565B2
A system for holding at least one of sample and reagent for analysis. The system includes a pair of parallel covers, at least one of which is light transmissive, of which pair a light transmissive cover forms a top, and of which pair the other forms a bottom. A frame is disposed between the covers to define, in relation to the covers, an interior volume.
Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US6716629B2
The invention features methods of making devices, or “platens”, having a high-density array of through-holes, as well as methods of cleaning and refurbishing the surfaces of the platens. The invention further features methods of making high-density arrays of chemical, biochemical, and biological compounds, having many advantages over conventional, lower-density arrays.
Selected Articles (3)
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
Nature Biotechnology2020-03-30
Modulation of chromatin structure via histone modification is a major epigenetic mechanism and regulator of gene expression. However, the contribution of chromatin features to tumor heterogeneity and evolution remains unknown. Here we describe a high-throughput droplet microfluidics platform to profile chromatin landscapes of thousands of cells at single-cell resolution. Using patient-derived xenograft models of acquired resistance to chemotherapy and targeted therapy in breast cancer, we found that a subset of cells within untreated drug-sensitive tumors share a common chromatin signature with resistant cells, undetectable using bulk approaches.
Dual indexed design of in-Drop single-cell RNA-seq libraries improves sequencing quality and throughput
BioRxiv2019-11-08
The increasing demand of single-cell RNA-sequencing (scRNA-seq) experiments, such as the number of experiments and cells queried per experiment, necessitates higher sequencing depth coupled to high data quality. New high-throughput sequencers, such as the Illumina NovaSeq 6000, enables this demand to be filled in a cost-effective manner.
Dual indexed library design enables compatibility of in-Drop single-cell RNA-sequencing with exAMP chemistry sequencing platforms
BMC Genomics2019-07-02
The increasing demand of single-cell RNA-sequencing (scRNA-seq) experiments, such as the number of experiments and cells queried per experiment, necessitates higher sequencing depth coupled to high data quality. New high-throughput sequencers, such as the Illumina NovaSeq 6000, enables this demand to be filled in a cost-effective manner.
Social